Search CORE

11 research outputs found

Generative models for music using transformer architectures

Author: OZTURK SILA
Publication venue
Publication date: 19/10/2023
Field of study

openThis thesis focus on growth and impact of Transformes architectures which are mainly used for Natural Language Processing tasks for Audio generation. We think that music, with its notes, chords, and volumes, is a language. You could think of symbolic representation of music as human language. A brief sound synthesis history which gives basic foundation for modern AI-generated music models is mentioned . The most recent in AI-generated audio is carefully studied and instances of AI-generated music is told in many contexts. Deep learning models and their applications to real-world issues are one of the key subjects that are covered. The main areas of interest include transformer-based audio generation, including the training procedure, encoding and decoding techniques, and post-processing stages. Transformers have several key advantages, including long-term consistency and the ability to create minute-long audio compositions. Numerous studies on the various representations of music have been explained, including how neural network and deep learning techniques can be used to apply symbolic melodies, musical arrangements, style transfer, and sound production. This thesis largely focuses on transformation models, but it also recognises the importance of numerous AI-based generative models, including GAN. Overall, this thesis enhances generative models for music composition and provides a complete understanding of transformer design. It shows the possibilities of AI-generated sound synthesis by emphasising the most current developments.This thesis focus on growth and impact of Transformes architectures which are mainly used for Natural Language Processing tasks for Audio generation. We think that music, with its notes, chords, and volumes, is a language. You could think of symbolic representation of music as human language. A brief sound synthesis history which gives basic foundation for modern AI-generated music models is mentioned . The most recent in AI-generated audio is carefully studied and instances of AI-generated music is told in many contexts. Deep learning models and their applications to real-world issues are one of the key subjects that are covered. The main areas of interest include transformer-based audio generation, including the training procedure, encoding and decoding techniques, and post-processing stages. Transformers have several key advantages, including long-term consistency and the ability to create minute-long audio compositions. Numerous studies on the various representations of music have been explained, including how neural network and deep learning techniques can be used to apply symbolic melodies, musical arrangements, style transfer, and sound production. This thesis largely focuses on transformation models, but it also recognises the importance of numerous AI-based generative models, including GAN. Overall, this thesis enhances generative models for music composition and provides a complete understanding of transformer design. It shows the possibilities of AI-generated sound synthesis by emphasising the most current developments

Padua Thesis and Dissertation Archive

Bifosfonat Kullanımına Bağlı Olarak Maksillada Kemik Nekrozu Oluşumu: Bir Olgu Sunumu

Author: Adnan Ozturk
Aysegul Tuzuner Oncul
Ayşegül Mine Tüzüner Öncül
Durmus Gorur
Durmuş İlker Görür
Kaan Orhan
Sila Sahin
Publication venue: 'Cumhuriyet University Faculty Dentistry'
Publication date: 01/01/2011
Field of study

Amaç: Bifosfonatlar, metastatik kemik kanserlerin önlenmesinde ve osteopörözün tedavisinde kullanılmaktadır. İntravenöz (i.v) bifosfonat (pamidronat, zoledronat) tedavisine bağlı olarak çene kemiklerinde osteonekroz gelişmektedir. Bu vaka raporu ile kliniğimize başvuran hastanın tedavisi sunulmuştur. Vaka Raporu: Kliniğimize başvuran 51 yaşındaki kadın hastada, uzun süreli intravenöz bifosfonat kullanımına bağlı sol maksilla molar bölgesinde asemptomatik osteonekroz görülmüştür. Hastaya gerekli debridman, sekestrasyon ve hiperbarik oksijen tedavisi uygulanmıştır. Hasta belirli aralıklarla takip edilmektedir. Sonuç: Bifosfonat kullanımına bağlı oluşan osteonekroz, i.v. bifosfonat kullanımının artmasına bağlı olarak daha sık görülmektedir. Bu nedenle bifosfonat tedavisi görecek olan hastaların oluşabilecek komplikasyonların engellenmesi amacıyla, tedavi öncesinde diş hekimine yönlendirilip, tüm dental tedavilerinin yapılması önerilmektedir

Directory of Open Access Journals

Bifosfonat Kullanımına Bağlı Olarak Maksillada Kemik Nekrozu Oluşumu: Bir Olgu Sunumu

Author: Adnan Ozturk
Aysegul Mine Tuzuner Oncul
Durmus Ilker Gorur
Kaan Orhan
sila sahin
Publication venue: 'Cumhuriyet University Faculty Dentistry'
Publication date: 01/01/2011
Field of study

Amaç: Bifosfonatlar, metastatik kemik kanserlerin önlenmesinde ve osteopörözün tedavisinde kullanılmaktadır. İntravenöz (i.v) bifosfonat (pamidronat, zoledronat) tedavisine bağlı olarak çene kemiklerinde osteonekroz gelişmektedir. Bu vaka raporu ile kliniğimize başvuran hastanın tedavisi sunulmuştur. Vaka Raporu: Kliniğimize başvuran 51 yaşındaki kadın hastada, uzun süreli intravenöz bifosfonat kullanımına bağlı sol maksilla molar bölgesinde asemptomatik osteonekroz görülmüştür. Hastaya gerekli debridman, sekestrasyon ve hiperbarik oksijen tedavisi uygulanmıştır. Hasta belirli aralıklarla takip edilmektedir. Sonuç: Bifosfonat kullanımına bağlı oluşan osteonekroz, i.v. bifosfonat kullanımının artmasına bağlı olarak daha sık görülmektedir. Bu nedenle bifosfonat tedavisi görecek olan hastaların oluşabilecek komplikasyonların engellenmesi amacıyla, tedavi öncesinde diş hekimine yönlendirilip, tüm dental tedavilerinin yapılması önerilmektedir. </p&gt

Directory of Open Access Journals

Differential expression of full-length and NH2 terminally truncated FAM134B isoforms in normal physiology and cancer.

Author: Atabey Nese
Bal Erhan
Cavga Ayse Derya
Ekin Umut
Iscan EVİN
Kahyaoglu Sila
Karakulah GÖKHAN
Keles Umur
Mutlu Zeynep
Ozturk Mehmet
SERDAR Muhittin Abdulkadir
SUNER KARAKÜLAH ASLI
Tasdemir Nilgun
Yilmaz Huriye Erbak
Publication venue: 'American Physiological Society'
Publication date: 01/01/2020
Field of study

Selective autophagy of the endoplasmic reticulum (ER), namely ER-phagy, is mediated by ER-localized receptors, which are recognized and sequestered by GABARAP/LC3B-decorated phagophores and transferred to lysosomes for degradation. Being one such receptor, FAM134B plays critical roles in cellular processes such as protein quality control and neuronal survival. FAM134B has also been associated with different cancers, although its exact role remains elusive. We report here that the FAM134B gene encodes not one but at least two different protein isoforms: the full-length and the NH2 terminally truncated forms. Their relative expression shows extreme variation, both within normal tissues and among cancer types. Expression of full-length FAM134B is restricted to the brain, testis, spleen, and prostate. In contrast, NH2 terminally truncated FAM134B is dominant in the heart, skeletal muscle, kidney, pancreas, and liver. We compared wild-type and knockout mice to study the role of the Fam134b gene in starvation. NH2 terminally truncated FAM134B-2 was induced in the liver, skeletal muscle, and heart but not in the pancreas and stomach following starvation. Upon starvation, Fam134b(-/-) mice differed from wild-type mice by less weight loss and less hyperaminoacidemic and hypocalcemic response but increased levels of serum albumin, total serum proteins, and a-amylase. Interestingly, either NH2 terminally truncated FAM134B or both isoforms were downregulated in liver, lung, and colon cancers. In contrast, upregulation was observed in stomach and chromophobe kidney cancers

Acibadem University Repository

PubMed Central

Dokuz Eylul University Research Information System

Intracardiac electrogram characteristics of intramural outflow tract ventricular arrhythmias

Author: Aksu Tolga
ATICI ADEM
Baysal Erkan
Bilge Ahmet Kaya
Ikitimur Baris
Mutlu Deniz
Oksul Metin
Onder Sukriye Ebru
Ozturk Sila
Soysal Ali Ugur
Tokdil Kardelen Nafia Inan Ohtaroglu
Yalin Kivanc
Yalman Hakan
Publication venue: 'Springer Science and Business Media LLC'
Publication date: 21/02/2023
Field of study

Background Annotation of earliest depolarization which depends on maximum dV/dt of unipolar-electrograms and unipolar QS morphology identify site of origin for ventricular premature contractions (VPC). However, identification of unipolar QS morphology has limitations due to low spatial resolution. This study aims to compare electrogram characteristics at successful ablation site in patients with outflow tract (OT) VPC. Methods Local activation time (LAT), duration, and voltage data of each bipolar- and unipolar-electrogram at the successful ablation sites from the right ventricle OT (RVOT) and the left ventricle OT (LVOT) cases were analyzed. Results Forty-four of 60 (73%) of patients were ablated from RVOT and in 16/60 (27%) required ablation from both sides. All patients had acute VPC suppression. Bipolar-electrogram-QRS onset was earlier (36.4 +/- 14.5 ms vs 26.3 +/- 7.4 ms, p = 0.01), duration of bipolar-electrogram was shorter (56.9 +/- 18.9 ms vs 78.9 +/- 21.8 ms, p = 0.002), and bi-voltage amplitude was higher (3.2 +/- 2.3 mV vs 1.4 +/- 1.1 mV, p = 0.07) for patients with RVOT-only ablation. Mean bipolar-unipolar-electrogram difference was 4.4 +/- 4.5 ms in the RVOT group vs 12.8 +/- 4.9 ms in RVOT + LVOT group (p < 0.001). Unipolar QS morphology was recorded in 3.0 +/- 3.9 vs 3.6 +/- 1.8 cm(2) in RVOT and RVOT + LVOT group, respectively (p = 0.41). Unipolar-electrogram revealed W pattern in 3/44 of RVOT vs 5/16 of RVOT + LVOT group, respectively (p = 0.01). In 18/60 (30%) of patients, unipolar QS was not identified at successful ablation site. Conclusion QS in unipolar-electrogram was not a perfect predictor for successful ablation sites. Analysis of bipolar voltage amplitude and duration with bipolar-unipolar-electrogram time difference may identify presence of a deeper source

İstanbul Üniversitesi Açık Erişim Sistemi

Is Perineural Invasio (PN) a Determinant of Disease Free Survival in Early Stage Colorectal Cancer?

Author: BOZKURTLAR EMİNE
Buyukunal Evin
DANE FAYSAL
Demirelli Fuat
Erdamar Sibel
Karagoz Sila
Mandel Nil Molinas
Ozguroglu Mustafa
Ozturk Mehmet Akif
Selcukbiricik Fatih
Serdengecti Suheyla
Tural Deniz
Turhal Nazim Serdar
Turna Hande
YUMUK PERRAN FULDEN
ÇELİKEL ÇİĞDEM
Publication venue: 'Update Medical Publishing'
Publication date: 01/01/2015
Field of study

Background/Aims: The prognostic importance of perineural invasion (PN) in colorectal cancer (CRC) is unclear. The aim of this study to find out whether the PN was an independent stratification factor of postoperative relapse in curatively resected high-risk stage II & III CRC patients who were treated with adjuvant therapy. Methodology: Data of patients with high risk stage II & all stage III CRCs treated with adjuvant chemotherapy were retrospectively analyzed. Pathological features of final surgical specimen were noted. Disease-free survival was determined by Kaplan-Meier estimator, with differences determined by multivariate analysis using the Cox multiple hazards model. Results were compared using the log-ranktest. Results: PN was found to be positive in 26% in the files of 593 eligible patients. In 21% of the reports PN status was not reported. Presence of PN in the resected primary tumors did not have independent effect on DFS. Further analyses for importance of PN on DFS of colon or rectal cancers did not show any effect. Conclusions: This study had failed to demonstrate any prognostic effect of PN for DFS in surgically resected stage II and III CRC patients who received adjuvant treatments

İstanbul Üniversitesi Açık Erişim Sistemi

Middle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study

Background In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. Results A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 +/- 12 years (interquartile range 37-55) and 532 (56.4%) of them were male. Total number of deaths was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; P = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) versus 4 (1.0%); P Conclusion The prevalence of ongoing respiratory symptoms increased in the first 3 months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different

PubMed Central

İstanbul Üniversitesi Açık Erişim Sistemi

Erciyes University - AVESIS

Awareness Of Hepatitis B Virus Reactivation Among Physicians Administering Immunosuppressive Treatment And Related Clinical Practices

Author: Acar Ali
Akdemir-Kalkan Irem
Akhan Sila
Aktug-Demir Nazlim
Arslan Eyup
Arslan-Ozeln Selcan
Asci Zerrin
Ayaz Celal
Aydin Gule
Aydinn Mehtap
Aygen Bilgehan
Batirel Ayse
Ceken Sabahat
Cetinkaya Riza Aytac
Ceylan Mehmet Resat
Demirturk Nese
Dirgen-Caylak Selmin
Eren-Kutsoylu Oya Ozlem
Ersoz Gulden
Gunal Ozgur
Gundogdu Kiymet
Gunes-Altiparmak Vuslat Ecem
Hakyemez Ismail Necati
Haykir-Solay Asli
Inan Dilara
Kadanali Ayten
Karagoz Ergenekon
Kocagul-Celikbas Aysel
Korkmaz Pinar
Kose Sukran
Kuruuzum Ziya
Ormen Bahar
Ozkaya Hacer Deniz
Ozturk Sinan
Saltoglu Nese
Sayan Murat
Sener Alper
Sirmatel Fatma
Sonmezer Meliha Cagla
Suer Huseyin Kaya
Sumer Sua
Tekin Suda
Toka Onur
Tulek Necla
Turker Nesrin
Ural Onur
Yenilmez Ercan
Yesilbag Zuhal
Yilmaz-Karadag Fatma
Yoruk Gulsen
Publication venue: 'AVES Publishing Co.'
Publication date: 01/01/2019
Field of study

Objective: This study aimed to evaluate the awareness and knowledge levels of all physicians administering immunosuppressive treatment concerning hepatitis B virus (HBV) reactivation, and draw attention to the importance of the subject through evaluation. Methods: The study was carried out by infectious diseases and clinical microbiology specialists in 37 health centers, and it was performed in Turkey between January and March 2017. All specialists providing a written consent and working in the departments of Medical Oncology, Hematology, Dermatology and Venereology, Physical Medicine and Rehabilitation, and Rheumatology of each study center were included in the study. Results: A total of 430 physicians participated in the study. Their mean age was 39.87 +/- 7.42 years, and 47.9% of them were males. During their career, 39.3% of these physicians had encountered patients developing HBV reactivation while receiving immunosuppressive treatment. The rate of encountering patients who died due to HBV reactivation was 6.5%. 97% of physicians who participated, considered the risk of HBV reactivation to be important. 70.2% of physicians stated that guidelines related to HBV reactivation and antiviral treatment for these patients were discussed in the congresses they participated, regarding their specialties. The rate of performing hepatitis screening among physicians whose patients developed HBV reactivation was statistically significantly higher than those physicians who had no patients with HBV reactivation (p<0.05). Physicians who used the guidelines related to HBV reactivation in their specialties performed screening for the HBV infection much more often than physicians who did not use the guidelines (p=0.002). Conclusions: According to the results obtained in our study, the rates of conducting screening and awareness of HBV reactivation among physicians administering immunosuppressive treatment were higher compared with similar studies; however, their awareness that HBV DNA and anti-HBc should be utilized much more frequently among the serological tests they use for screening of HBV infection, should be increased.WoSScopu

Hacettepe University Institutional Repository

Kütahya Health Sciences University Research Information System

İstanbul Üniversitesi Açık Erişim Sistemi

Erciyes University - AVESIS

Dokuz Eylul University Research Information System

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Author: Abdelhamid N.
Abdul Rahman D.
Abdul-Saheb M.
Abreu P.
Abroskina M.
Abu Ahmad F.
Accassat S.
Acciaresi M.
Adami A.
Ahmad N.
Ahmed F.
Alberto Hawkes M.
Alemseged F.
Ali A.
Altavilla R.
Alwis L.
Amarenco P.
Amaro S.
Amaya Sanchez L. E.
Amelia Pinto A.
Ameriso S. F.
Ameriso Sebastian F
Amin H.
Amino T.
Amjad A. K.
Anagnostou E.
Andersen G.
Anderson C.
Anderson D. C.
Andrea Falco M.
Andres Mackinnon F.
Andreu D.
Androulakis M.
Angel Gamero M.
Angel Saredo G.
Angeles Diaz R.
Angels Font M.
Anticoli S.
Arauz Gongora A. A.
Arauz A.
Araya P.
Arenillas Lara J. F.
Arias Rivas S.
Arnold M.
Augustin S.
Avelar W.
Azevedo E.
Babikian V.
Bacellar A.
Badalyan K.
Bae H. J.
Baez Martinez E. M.
Bagelmann H.
Bailey P.
Bak Z.
Baker M.
Balazs A.
Baldaranov D.
Balogun I.
Balueva T.
Bangdiwala Shrikant
Bankuti Z.
Bar M.
Baranowska A.
Bardutzky J.
Barker Trejo S.
Barlinn J.
Baronnet F.
Barroso C.
Barteys M.
Bartolottiova T.
Barulin A.
Bas M.
Bashir S.
Basile V.
Bathe-Peters R.
Bathula R.
Batista C.
Batur Caglayan H.
Baumgartner P.
Bazan R.
Bazhenova O.
Beaudry M.
Beer J.
Behnam Y.
Beilei C.
Beinlich A.
Bejot Y.
Belkin A.
Benavente O. R.
Benjamin A.
Berardi V.
Bereczki D.
Berkowitz S. D.
Berkowitz Scott D
Berlingieri J.
Berrios W.
Berrouschot J.
Bhandari M.
Bhargavah M.
Bicker H.
Bicsak T.
Bilik M.
Bindila D.
Birchenall J.
Birnbaum L.
Black T.
Blacker D.
Blacquiere D.
Blanc-Labarre C.
Blank C.
Blazejewska-Hyzorek B.
Bloch S.
Bodiguel E.
Bogdanov E.
Boos L.
Borcsik L.
Bornstein N.
Bouly S.
Braga G.
Bragado I.
Bravi M. C.
Brokalaki C.
Brola W.
Brouns R.
Bruce D.
Brzoska-Mizgalska J.
Buck B.
Buksinska-Lisik M.
Burke J.
Burn M.
Bustamante G.
Cabrejo L.
Cai K.
Cajaraville S.
Calejo M.
Calvet D.
Campillo J.
Campos Costa E.
Camps P.
Can Alaydin H.
Candeloro E.
Canepa C.
Cantu Brito C. G.
Cappellari M.
Carcel C.
Cardona Portela P.
Cardoso F.
Carek M.
Carletti M.
Carlos Portilla J.
Caruso P.
Casado-Naranjo I.
Castellini P.
Castro Meira F.
Castro D.
Cavallini A.
Cayuela Caudevilla N.
Cenciarelli S.
Cereda C.
Cerrone P.
Chakrabarti A.
Chaloulos-Iakovidis P.
Chamorro A.
Chandrasena D.
Chang D. I.
Che C.
Chembala J.
Chen G.
Chen H.
Chen H.
Chen J.
Chen J.
Chen J.
Chen L.
Chen S.
Chen T.
Chen X.
Chen Z.
Cheripelli B.
Chin M.
Chiquete Anaya E.
Chorazy M.
Christensen H.
Christensen T.
Christian L.
Chu F.
Chung C. S.
Clark W.
Clarke R.
Claverie S.
Clemente Agostoni E.
Clissold B.
Coelho J.
Cohen D.
Colakoglu S.
Collas D.
Condurso R.
Connolly S. J.
Connolly Stuart J
Consoli D.
Constantin C.
Constantino Silva A. B.
Contardo L.
Corlobe A.
Correia C.
Correia M.
Cortijo Garcia E.
Coull B.
Coutts S.
Coveney S.
Cras P.
Crols R.
Crozier S.
Csanyi A.
Csiba L.
Csontos K.
Csuha R.
Cui L.
Cunha L.
Curtze S.
Czerska M.
Czlonkowska A.
Czurko M.
Czuryszkiewicz M.
Dagnino M.
Dai C.
Daineko A.
Dalek G.
Damgaard D.
Danese A.
Dani K.
Danku V.
Dario Toledo W.
De Havenon A.
De Keyser J.
De Klippel N.
De La Torre J.
De Pauw A.
De Smedt A.
De Torres R.
De Vries Basson M. M.
Dearborn J.
Deganutto R.
Degeorgia M.
Deguchi I.
Del Giudice A.
Delcourt C.
Delgado-Mederos R.
Della Marca G.
Delpont B.
Deltour S.
Demets D. L.
Dennis M.
Desai J.
Devine J.
Dhollander I.
Di Mascio M. T.
Diaconu M.
Diaz Otero F.
Dietzel J.
Diez-Tejedor E.
Ding J.
Ding J.
Ding N.
Diomedi M.
Dioszeghy P.
Distefano M.
Domigo V.
Dorodnicov E.
Dossi D.
Doubal F.
Druzenko I.
Du J.
Du P.
Duman T.
Duodu Y.
Dutta D.
Dylewicz L.
Dávalos A.
Eckstein J.
Ehrensperger E.
Ehrlich S.
Einer Allende G.
Elena Halac B.
Elyas S.
Endres M.
Endres Matthias
Engelbrecht J. M.
Engelter S.
Epinat M.
Eren F.
Esbjornsson M.
Escribano B.
Escudero I.
Esisi B.
Essa B.
Esterbauer M.
Evans N.
Eveson D.
Fabio S.
Fang L.
Fanta S.
Fares M.
Fatar M.
Faust K.
Favate A.
Fazekas F.
Federica Denaro M.
Fedin A.
Felipe Amaya P.
Feng J.
Ferencova K.
Fernanda Gilli M.
Fernandez Pirrone P. N.
Fernandez Vera J.
Fernandez M. D.
Ferrari J.
Ferreira Junior G.
Ferreira A.
Fidler M.
Field D.
Field T.
Figueroa C.
Fiksa J.
Filipov A.
Firstenfeld A.
Fisch L.
Fischer U.
Fisselier M.
Fiszer U.
Fluri F.
Fortea G.
Fotherby K.
Fraczek A.
France E.
Freitas G.
Frey S.
Frick M.
Friedman A.
Friedrich M.
Frisullo G.
Fryze W.
Fuentes Gimeno B.
Fujigasaki H.
Fukuyama K.
Furlan A.
Furlanis G.
Furnace J.
Gabriel Reich E.
Gabriel M.
Gagliardi R. J.
Galati F.
Galli Giqueauk E.
Gallina A.
Gallinella E.
Gallo J.
Gangadharan S.
Gao Y.
Garcia Lopez R.
Garcia Pastor A.
Garcia Sanchez S. M.
Garnauf M.
Garnier P.
Gasecki D.
Gasic K.
Gasiorek K.
Gasser S.
Gaugg M.
Gebreyohanns M.
Gebura K.
Geng J.
Geniz Clavijo M.
Georg Haeusler K.
Geran R.
Geremek M.
Gerocs Z.
Ghia D.
Giannandrea D.
Giatsidis F.
Gien Lopez J. A.
Gil Nunez A.
Gimenez L.
Giralt E.
Glabinski A.
Gladstone D.
Gliem M.
Gluszkiewicz M.
Goddeau R.
Gogoleva E.
Gokce M.
Goldemund D.
Golikov K.
Gomes Neto A.
Gomez Schneider M.
Gomez-Choco M.
Gomis M.
Gongora-Rivera J. F.
Gonysheva Y.
Gonzalez Toledo M. E.
Gonzalez L.
Gottschal M.
Gozdzik I.
Grabowski S.
Graf S.
Green D.
Greer D.
Gregorio T.
Greisenegger S.
Greshnova I.
Griebe M.
Grosse G. M.
Grzesik M.
Guan J.
Guarda S.
Gueguen A.
Guidoux C.
Guillermo Povedano P.
Guillon B.
Guiraudg V.
Gunathilagan G.
Guryanova N.
Gusev V.
Gustavo Persi G.
Gutiérrez R.
Guyler P.
Gyuker N.
Hachinski V.
Hajas A.
Hallevi H.
Hankey G.
Hankey G. J.
Hanouskova L.
Hao L.
Haraguchi K.
Haralur Sreekantaiah Y.
Haratz S.
Hargroves D.
Harkness K.
Harmel P.
Harrasser M.
Hart R. G.
Hart Robert G
Harvey M.
Hasan R.
Hasegawa Y.
Hassan A.
Hattori M.
Hatzitolios A.
Hauk M.
Hayashi T.
Hayhoe H.
Hedna V. S.
Heine M.
Held V.
Hellwig S.
Henkner J.
Henninger N.
Hermans S.
Hernandez J.
Herrero D.
Hervieu-Begue M.
Herzig R.
Hicken L.
Hieber M.
Hill M.
Hirose M.
Hobeanu M. C.
Hobson B.
Hochstetter M.
Hoe Heo J.
Hoffmann M.
Holmstedt C.
Hon P.
Hong K. S.
Honma Y.
Horev A.
Horgan G.
Horvath L.
Horvath M.
Hoyer C.
Huang D.
Huang H.
Huber B.
Huhtakangas J.
Hussain M.
Igarashi S.
Iglesias Mohedano A. M.
Ignacio Tembl J.
Impellizzeri M.
Inanc Y.
Ioli P.
Irina Aniculaesei A.
Ishida K.
Itabashi R.
Iversen H.
Jagolino A.
Jakab K.
Jander S.
Janka H.
Jankovych J.
Jansen J.
Jasek L.
Javier Alet M.
Javor L.
Jin X.
Jing P.
Joachim B.
Joan Macleod M.
Johnson M.
Jose Martin J.
Joyner C.
Judit Szabo K.
Jun-Oconnell A.
Jura R.
Kaczorowska B.
Kadlcikova J.
Kahles T.
Kakaletsis N.
Kakuk I.
Kalinowska K.
Kaminska K.
Kaneko C.
Kanellos I.
Kapeller P.
Kapica-Topczewska K.
Karasz O.
Karlinski M.
Karlsson J. E.
Kasa K.
Kashaeva E.
Kasner S. E.
Kasner Scott E
Kaste M.
Kasza J.
Katalin Iljicsov A.
Katsurayama M.
Kaur S.
Kawanishi M.
Kaygorodtseva S.
Ke K.
Kei A.
Keilitz J.
Kellner J.
Kelly P.
Kelly S.
Kemlink D.
Kerekgyarto M.
Keskinarkaus I.
Khairutdinova D.
Khanna A.
Khaw A.
Kholopov M.
Khoumri C.
Kirpicheva S.
Kirshner H.
Kitagawa K.
Kittner S.
Kivioja R.
Klein F.
Kleindorfer D.
Kleinig T.
Klivenyi P.
Knecht S.
Kobayashi A.
Kobayashi Y.
Koch M.
Koehler L.
Koivu M.
Kolianov V.
Koltsov I.
Kondo T.
Konkov I.
Kopecky S.
Korompoki E.
Korpela J.
Kosarz-Lanczek K.
Koutroubi A.
Kovacs H.
Kovacs K.
Kovacs T.
Kowalczyk K.
Kowalska M.
Krajickova D.
Kral M.
Krarup Hansen C.
Kraska J.
Krebs S.
Krejci V.
Kremer C.
Kreuzpointer R.
Krzyzanowska M.
Kucken D.
Kulakowska A.
Kunzmann J.
Kurenkova N.
Kuris A.
Kurkowska-Jastrzebska I.
Kurtenkova N.
Kurushina O.
Kusnick G.
Kustova M.
Kuwashiro T.
Kwan Cha J.
Lago A.
Lagutenko M.
Lajos B.
Lambeck J.
Lamy C.
Landolfi A.
Lanfranconi S.
Lang W.
Lara Lezama L. B.
Lara Rodriguez B.
Largo T.
Lasek-Bal A.
Latte L.
Lauer V.
Lavados P.
Lavados Pablo
Le Bouc R.
Leal Cantu R.
Lechner H.
Lecouturier K.
Leder S.
Lee B. C.
Lee J.
Leger A.
Leira E.
Leisse I.
Leker R.
Lembo G.
Lenskaya L.
Leyden J.
Li G.
Li J.
Li M.
Li S.
Liamis G.
Liang H.
Liang Z.
Ligot N.
Lin H.
Lindert R.
Lindgren A.
Lindgren Arne
Linna M.
Litwin T.
Liu K.
Liu X.
Llull L.
Lohninger B.
Longoni M.
Loomis C.
Lopes D.
Lopez Fernandez M.
Lopez Garza N.
Lord A.
Louw S.
Lovasz R.
Lowenkopf T.
Lu Z.
Lubke-Detring S. C.
Luder R.
Lujan S.
Luo B.
Lupinogina L.
Luschin G.
Lutsep H.
Lutsep Helmi
Lvova A.
Ly J.
Ma C.
Ma H.
Machado C.
Machado M.
Macher S.
Machetanz J.
Macian-Montoro F.
Mackey A.
Mackey E.
Maclean G.
Maestre-Moreno J.
Magadan A.
Magyar T.
Mahagney A.
Majid A.
Majjhoo A.
Makaritsis K.
Mandzia J.
Mangas Guijarro M.
Mangion D.
Manios E.
Mann S.
Manning L.
Manno C.
Manuel Garcia J.
Maqueda V.
Mar Castellanos M.
Mar Freijo M.
Marando C.
Marcela Lepera S.
Marcos Couto J.
Maria Bruera G.
Maria Greco L.
Maria Lorenzo A.
Maria Obmann S.
Maria Roa A.
Marini C.
Marinkovic I.
Mario Sumay G.
Mario Torres C.
Marko M.
Markova S.
Markus H.
Marsh R.
Marsili E.
Marta Esnaola M.
Marta Moreno J.
Marti-Fabregas J.
Martina Angelocola S.
Martinez-Majander N.
Martins S.
Martínez Sánchez P.
Marzelik O.
Mastrocola S.
Matamala G.
Matoltsy A.
Matosevic B.
Matsumoto S.
Maud A.
Mauri Cabdevila G.
May Z.
Mayasi Y.
Mayr A.
Mazzoli T.
Mcarthur K.
Mccullough L.
Medina Pech C. E.
Medlin F.
Mehdiratta M.
Mehta B.
Mehta D.
Mehta S.
Melis M.
Melnikova E.
Mendez B.
Mendonca T.
Mengual Chirifie J. J.
Menon N.
Mensch A.
Meseguer E.
Messe S.
Messé Steven R
Metcalf K.
Meyer N.
Michas F.
Micheletti N.
Mikulik R.
Milionis H.
Miller B.
Milling T.
Minelli C.
Minhas J.
Minns M.
Mircea D.
Mishra S.
Mismas A.
Mistri A.
Mitrovic N.
Miyake H.
Modrau B.
Moey A.
Molina C.
Molina J.
Molis A.
Moller J.
Molnar S.
Moniche F.
Monosi C.
Monzani V.
Moonis M.
Morais R.
Morales A.
Morales L.
Morar-Precup D.
Moreton F.
Moro C.
Morozova E.
Morton M.
Morvan E.
Morvan T.
Motko T.
Mowla A.
Mozhejko E.
Muddegowda G.
Mudhar O.
Mueller T.
Muhl C.
Muir K. W.
Muir Keith
Mundl H.
Mundl Hardi
Munoz S.
Murphy C.
Murphy S.
Murtuzova A.
Musuka T.
Mutzenbach J.
Myint M.
Mysliwy W.
Naccarato M.
Naeije G.
Nagakane Y.
Natarajan I.
Navaratnam D.
Nave A.
Nazliel B.
Nedeltchev K.
Nedeltechev Krassen
Nel J.
Nell H.
Nemeth L.
Nemeth R.
Neto O.
Ng K.
Ngeh J.
Nicolas Chialvo L.
Nieminen T.
Nikkanen M.
Nikl J.
Nikoforova M.
Nishino S.
Nishiyama Y.
Njovane X.
Nogawa S.
Nombela F.
Norrving B.
Nosek K.
Nowak B.
Nowakowska-Sledz E.
Ntaios G.
Numminen H.
Nunez F.
O'Donnell M. J.
Obadia M.
Oberndorfer S.
Obrezan A.
Ochiai J.
Oczkowski W.
Odyniec A.
Oh K.
Ohira M.
Okamoto Y.
Okpala M.
Okubo S.
Olah L.
Olavarria V.
Olavarria Veronica
Oleszek J.
Onat Demirci N.
Ondar V.
Ongun G.
Ooyama K.
Orosz V.
Ortiz R.
Osseby G.
Ovesen C.
Ozcekic Demirhan S.
Ozdoba-Rot J.
Ozturk S.
Ozyurt E.
Pablo Grecco M.
Pablo Povedano G.
Paciaroni M.
Padiglioni C.
Pagola J.
Palasik W.
Panczel G.
Panos L.
Papadopoulos G.
Papadopoulou E.
Papagiannis A.
Papavasileiou V.
Papina M.
Pardo De Donlebun J. R.
Parisi V.
Park J. M.
Pasten J.
Patel N.
Pavlik O.
Pawelczyk M.
Peacock W. F.
Pei H.
Peisker T.
Pena Sedna L. F.
Penn A.
Pentek S.
Pepper E.
Pereira L.
Perera K.
Perera Kanjana
Perez Leguizamon P.
Perez S.
Perez Y.
Pernicka M.
Perry R.
Persico A.
Pesant Y.
Peska S.
Peters D.
Peters G.
Pettigrew L.
Phan T.
Philippi S.
Phinney T.
Pico F.
Pidal A.
Piechowski-Jozwiak B.
Pieroni A.
Pineiro S.
Piras V.
Pizova N.
Polanco J.
Polin M.
Polyakov A.
Polychronopoulou E.
Polymeris A.
Popov D.
Poppe A.
Postorino P.
Pozzerese C.
Pradhan M.
Prats L.
Prazdnichkova E.
Prendl B.
Pretorius M.
Profice P.
Prokopenko S.
Pudov E.
Pujol Lereis V.
Punzo Bravo G.
Purroy F.
Qiu J.
Qu X.
Quenardelle V.
Quesada Garcia H.
Radrizzani L.
Radtke A.
Raffelsberger T.
Ramirez Moreno J. M.
Ramos-Estebanez C.
Rani A.
Rapantova P.
Rashed K.
Rasheed Nihara A.
Rasmussen J.
Redondo Robles L.
Reif M.
Reiner P.
Rekova P.
Renu A.
Repetto M.
Reyes Morales S.
Reyes P.
Rha J. H.
Ribeiro J.
Ricci S.
Richard C.
Rigual R.
Rinaldi C.
Riveira Rodriguez C.
Rizzato B.
Robinson T. G.
Rocco A.
Rodrigues M.
Rodriguez Campello A.
Rodriguez Lucci F.
Rodriguez Yanez M.
Rodriguez G.
Roesler C.
Roffe C.
Roine R.
Roine S.
Roldan A.
Romana Pezzella F.
Romano M.
Roos J. S.
Rosso C.
Rostrup Kruuse C.
Roth Y.
Roukens R.
Roveri L.
Rozanski D.
Rozniecki J.
Rozsa C.
Rudilosso S.
Ruiz Ares G.
Ruiz Franco A.
Rum G.
Ruuskanen J.
Rybinnik I.
Ryota K.
Saarinen J.
Saavedra V.
Sabben C.
Sabet A.
Sagris D.
Sahlas J.
Sakai N.
Salamanca P.
Salgado P.
Salig S.
Salletmayr T.
Salnikov M.
Samoshkina O.
Samson Y.
Sanak D.
Santalucia P.
Santamaria Cadavid M.
Santiago P.
Santo G.
Santo Gustavo
Sanz Cuesta B.
Sargento J.
Sarraj A.
Sas A.
Sas K.
Satoshi O.
Satsoglou S.
Sattar N.
Savitz S.
Savopoulos C.
Saw J.
Sawicka M.
Sawyer R.
Scandura T.
Schillinger N.
Schindler J.
Schlachetzki F.
Schneider I.
Schuppner R.
Schurig J.
Schwarzbach C. J.
Sebejova M.
Seidel G.
Sekaran L.
Selcuk D.
Selvarajah J.
Semerano A.
Semjen J.
Semushina D.
Sen S.
Seok Park M.
Serena J.
Serhat Tokgoz O.
Serles W.
Serrano F.
Sevin M.
Seynaeve L.
Shah S.
Shamalov N.
Shang T.
Sharma M.
Sharma Mukul
Sharrief A.
Shazam Hussain M.
Shchukin I.
Shen W.
Shepeleva E.
Shinsuke I.
Shmonin A.
Shoamanesh A.
Shoamanesh Ashkan
Shuaib A.
Shulga A.
Sibolt G.
Sibon I.
Sicilia I.
Siebert M.
Sieczkowska E.
Sila C.
Silva A. A.
Silva D.
Silva P.
Silva Y.
Silvestrini M.
Simony Z.
Simpkins A.
Singh B.
Sinha D.
Sipos I.
Skoda O.
Skowron P.
Skowronska M.
Sliwinska B.
Slonkova J.
Smolkin A.
Smyth A.
Sobolewski P.
Sobota A.
Sohn S. I.
Soldatov M.
Solganov I.
Soloveva L.
Solovyeva E.
Sonntag N.
Soors P.
Sorgun M.
Soriano C.
Spence D.
Spence J David
Spengos K.
Sposato L.
Staaf G.
Stadler K.
Stakhovskaya L.
Stamatelopoulos K.
Steinert S.
Stetkarova I.
Stiehm M.
Stocker R.
Stoinski J.
Stoll A.
Stotts G.
Stumpp A.
Sucapane P.
Suenaga T.
Sun X.
Sundararajan S.
Sung Kim J.
Suzuki H.
Svaneborg N.
Swaminathan Balakumar
Szasz G.
Szczuchniak W.
Szczyrba S.
Szegedi N.
Szekely A.
Szewczyk Z.
Szilagyi G.
Szlufik S.
Szoboszlai K.
Szpisjak L.
Sztajzel R.
Sztriha L.
Sànchez Cerón M.
Ta Wil S. E.
Taggeselle J.
Takamatsu K.
Takao M.
Taki W.
Takizawa S.
Talahma M.
Tamayo A.
Tan J.
Tanne D.
Tapanainen A.
Tapiola T.
Tarasiuk J.
Tatlisumak T.
Tayal A.
Tcvetkova S.
Teal P.
Tejada Garcia J.
Tejada Meza H.
Tenora D.
Terceno M.
Terentiou A.
Tezcan S.
Thaler D.
Thomson A.
Thouvenot E.
Tiainen M.
Timberg I.
Timsit S.
Tinchon A.
Tirschwell D.
Togay Isikay C.
Tokunaga K.
Tolino M.
Toloza C.
Tomelleri G.
Tomoyuki K.
Tomppo L. M.
Tong L.
Tong Z.
Toni D.
Torres J.
Tossavainen C.
Toth G.
Tountopoulou A.
Touze E.
Tovar M.
Toyoda K.
Trillo S.
Trommer A.
Tropepi D.
Tryambake D.
Tu H.
Tuetuencue S.
Tumova R.
Tumpula O.
Turc G.
Tutaj A.
Tynkkynen J.
Uchiyama S.
Uchwat U.
Uhrinyakova L.
Ulku Acar R.
Uluduz Ugurlu D.
Urra X.
Urui S.
Usero Ruiz M.
Vaclavik D.
Vahedi K.
Valikovics A.
Valpas J.
Van Acker P.
Van Daele W.
Vanderschueren G.
Vanina Jure L.
Varela R.
Varga Z.
Varvat J.
Varvyanskaya N.
Vasco Salgado A.
Vasko P.
Vass L.
Vassilopoulou S.
Vastagh I.
Vazquez P.
Vecsei L.
Veltkamp R.
Veltkamp Roland
Venti M.
Verdugo M.
Verocai V.
Veronica Marroquin M.
Veronica Simonsini C.
Veverka T.
Vigl M.
Vila A.
Vilar C.
Villanueva Osorio J. A.
Virta J.
Vitkova E.
Voglsperger B.
Volna J.
Von Weitzel-Mudersbach P. A.
Vora N.
Voznyuk I.
Wach-Klink A.
Wacongne A.
Walters D.
Wang D.
Wang H.
Wang J.
Wang L.
Wang N.
Wang W.
Wang X.
Wang X.
Wang Y.
Wang Y.
Wang Y.
Wang Y.
Warnack W.
Wartenberg K.
Waters M.
Waters R.
Webb T.
Weber J.
Weiss G.
Weissenborn K.
Weitz J. I.
Weller B.
Wen G.
Weng G.
Werner P.
Werring D.
Wester P.
Whiteley W.
Whiting R.
Wijeratne T.
Willems C.
Wilson C.
Wilson L.
Winder T.
Windt J.
Winkler A.
Winska-Tereszkiewicz A.
Wisniewska A.
Wittayer M.
Wlodek A.
Wojnarowska-Arendt A.
Wolf M.
Wolff V.
Wolter C.
Wong A.
Wook Nah H.
Worthmann H.
Wu S.
Wu W.
Wunderlich S.
Wurzinger H.
Wyse D. G.
Xiao B.
Xiaopeng W.
Ximenez-Carrillo A.
Xiong L.
Xiong W.
Xiong Y.
Xu J.
Xu Y.
Xu Z.
Yalo B.
Yamada T.
Yamasaki M.
Yang B.
Yang J.
Yang L.
Yang Q.
Yang X.
Yang Y.
Yang Y.
Yasuhiro I.
Yee Lam M.
Yegappan C.
Yip S.
Ylikallio E.
Ylikotila P.
Yongwon Jin A.
Yoon B. W.
Yoshida Y.
Yperzeele L.
Yuan H.
Yuasa H.
Zalewska J.
Zanferrari C.
Zapata E.
Zboznovits D.
Zelenka I.
Zhang B.
Zhang C.
Zhang J.
Zhang M.
Zhang S.
Zhang X.
Zhao L.
Zhirnova O.
Zhou L.
Zielinska-Turek J.
Zinchenko I.
Ziomek M.
Zitzmann A.
Zweifler R.
Zwiernik J.
Österlund-Tauriala E.
Publication venue: 'Elsevier BV'
Publication date: 01/01/2018
Field of study

Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial. Methods: NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy. Findings: Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity. Interpretation: Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted. Funding: Bayer and Janssen

PubliCatt

ART

Archivio della ricerca- Università di Roma La Sapienza